Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Federal Trade Commission
Citi
Chubb
Merck
Daiichi Sankyo
Queensland Health
Fuji
Chinese Patent Office

Generated: October 20, 2017

DrugPatentWatch Database Preview

DOCETAXEL - Generic Drug Details

« Back to Dashboard

What are the generic sources for docetaxel and what is the scope of docetaxel freedom to operate?

Docetaxel
is the generic ingredient in three branded drugs marketed by Apotex Inc, Sandoz, Sun Pharma Global, Hospira Inc, Eagle Pharms, Sanofi Aventis Us, Actavis Llc, Jiangsu Hengrui Med, Pfizer Labs, Ingenus Pharms Llc, Dfb Oncology Ltd, Teva Pharms Usa, Dr Reddys Labs Ltd, and Accord Hlthcare, and is included in fifteen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Docetaxel has fifteen patent family members in fifteen countries and three supplementary protection certificates in three countries.

There are forty drug master file entries for docetaxel. Fifteen suppliers are listed for this compound.

Summary for Generic Name: DOCETAXEL

US Patents:2
Tradenames:3
Applicants:14
NDAs:15
Drug Master File Entries: see list40
Suppliers / Packagers: see list15
Bulk Api Vendors: see list59
Clinical Trials: see list1,827
Patent Applications: see list9,949
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:DOCETAXEL at DailyMed

Pharmacology for Ingredient: DOCETAXEL

Drug ClassMicrotubule Inhibitor
Physiological EffectMicrotubule Inhibition
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eagle Pharms
DOCETAXEL
docetaxel
SOLUTION;IV (INFUSION)205934-001Dec 22, 2015RXNoNo► Subscribe► SubscribeY ► Subscribe
Accord Hlthcare
DOCETAXEL
docetaxel
INJECTABLE;INJECTION201195-005Apr 20, 2012APRXYesYes► Subscribe► Subscribe► Subscribe
Dfb Oncology Ltd
DOCETAXEL
docetaxel
INJECTABLE;INJECTION206177-002Jan 20, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Hospira Inc
DOCETAXEL
docetaxel
INJECTABLE;INJECTION022234-006Jun 23, 2016DISCNYesNo► Subscribe► Subscribe► Subscribe
Sun Pharma Global
DOCEFREZ
docetaxel
INJECTABLE;INJECTION022534-002May 3, 2011DISCNYesNo► Subscribe► Subscribe► Subscribe
Hospira Inc
DOCETAXEL
docetaxel
INJECTABLE;INJECTION022234-002Mar 8, 2011APRXYesYes► Subscribe► Subscribe► Subscribe
Ingenus Pharms Llc
DOCETAXEL
docetaxel
INJECTABLE;INJECTION207563-003Aug 31, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
DOCETAXEL
docetaxel
INJECTABLE;INJECTION022312-001Jan 11, 2012DISCNNoNo► Subscribe► Subscribe► Subscribe
Sandoz
DOCETAXEL
docetaxel
INJECTABLE;INJECTION201525-002Jun 29, 2011APRXNoNo► Subscribe► Subscribe► Subscribe
Hospira Inc
DOCETAXEL
docetaxel
INJECTABLE;INJECTION022234-004Jun 23, 2016RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: docetaxel

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
TAXOTERE
docetaxel
INJECTABLE;INJECTION020449-001May 14, 1996► Subscribe► Subscribe
Sanofi Aventis Us
TAXOTERE
docetaxel
INJECTABLE;INJECTION020449-004Aug 2, 2010► Subscribe► Subscribe
Sanofi Aventis Us
TAXOTERE
docetaxel
INJECTABLE;INJECTION020449-003Aug 3, 2010► Subscribe► Subscribe
Sanofi Aventis Us
TAXOTERE
docetaxel
INJECTABLE;INJECTION020449-001May 14, 1996► Subscribe► Subscribe
Sanofi Aventis Us
TAXOTERE
docetaxel
INJECTABLE;INJECTION020449-004Aug 2, 2010► Subscribe► Subscribe
Sanofi Aventis Us
TAXOTERE
docetaxel
INJECTABLE;INJECTION020449-001May 14, 1996► Subscribe► Subscribe
Sanofi Aventis Us
TAXOTERE
docetaxel
INJECTABLE;INJECTION020449-003Aug 3, 2010► Subscribe► Subscribe
Sanofi Aventis Us
TAXOTERE
docetaxel
INJECTABLE;INJECTION020449-004Aug 2, 2010► Subscribe► Subscribe
Sanofi Aventis Us
TAXOTERE
docetaxel
INJECTABLE;INJECTION020449-003Aug 3, 2010► Subscribe► Subscribe
Sanofi Aventis Us
TAXOTERE
docetaxel
INJECTABLE;INJECTION020449-001May 14, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: docetaxel

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,763,880Non-aqueous taxane formulations and methods of using the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: docetaxel

Country Document Number Estimated Expiration
Russian Federation2015116260► Subscribe
South Korea20150066542► Subscribe
European Patent Office2903435► Subscribe
India2661DEN2015► Subscribe
Argentina092759► Subscribe
Hong Kong1210665► Subscribe
World Intellectual Property Organization (WIPO)2014055426► Subscribe
Philippines12015500681► Subscribe
Taiwan201417842► Subscribe
Canada2885930► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: DOCETAXEL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
60002Netherlands► SubscribePRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127
/2013Austria► SubscribePRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
172Luxembourg► SubscribePRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Merck
Chinese Patent Office
Cerilliant
Dow
Novartis
Moodys
Accenture
Cipla
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot